The recent development ofKRASG12C inhibitors, which target the most common mutant form of theprotein in lung cancer, has shown that inhibiting KRAS-signalling in tumour cellspromotes anti-tumour immune responses and synergises with anti-PD-1 therapy in animmune-competent model of colorectal cancer (7). The gene discussed is KRAS; the disease is neoplasm.